ABT · Healthcare
ABBOTT LABORATORIES
Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window
News · 2026-09-23
- Partner Ecosystem ExpansionImportance 31 · Surprise 42Abbott partnered with Berry Street to combine its Lingo continuous glucose monitor with Berry Street’s insurance-covered registered dietitian support. The offering gives Lingo users virtual one-on-one nutrition…
- Product Launch and TransitionImportance 31 · Surprise 42Abbott launched its Volt Pulsed Field Ablation System in the United States and Canada. The launch expands Abbott’s electrophysiology product portfolio into two North American markets and is described as a source of…
News · 2026-09-22
- Infant Formula LitigationImportance 53 · Surprise 60Abbott agreed to pay approximately $385 million to resolve U.S. Department of Justice, federal, and state allegations concerning unsanitary conditions and false claims at infant-formula facilities. The settlement…
News · 2026-09-17
- Quarterly Dividend DeclarationImportance 6 · Surprise 6Abbott’s board declared a quarterly common dividend of $0.63 per share on September 17, 2026. The payment represents Abbott’s 411th consecutive quarterly dividend. The digest does not provide the aggregate cash cost,…
News · 2026-09-15
- Infant Formula Regulatory CaseImportance 40 · Surprise 42Abbott agreed to pay approximately $385 million to resolve U.S. Department of Justice allegations related to contaminated infant formula produced at its Michigan and Arizona facilities. The investigation followed the…
- Infant Formula LitigationImportance 40 · Surprise 42Abbott agreed to pay $385 million to resolve U.S. Justice Department allegations related to contaminated infant formula produced during a 2022 investigation that led to the closure of its largest plant. The settlement…
- CGM Competition and PricingImportance 34 · Surprise 42Beta Bionics received FDA clearance for Mint, a new insulin patch pump with a reusable and disposable architecture that does not require recharging. The pump integrates with Abbott’s FreeStyle Libre 3 Plus continuous…
News · 2026-09-14
- Infant Formula LitigationImportance 53 · Surprise 60Abbott agreed to pay approximately $384 million to resolve U.S. Department of Justice allegations and related federal and state lawsuits concerning its 2022 powdered infant-formula recall. The matter relates to…
News · 2026-09-10
- Spinal Stimulator LitigationImportance 31 · Surprise 42A South Carolina woman filed a product liability lawsuit alleging that Abbott’s Proclaim spinal cord stimulator malfunctioned and caused painful electrical shocks, burning sensations, and worsening pain. The alleged…
News · 2026-09-09
- Regulatory Approval MilestonesImportance 38 · Surprise 60Abbott received U.S. FDA clearance for the TactiFlex Duo ablation catheter to treat atrial fibrillation. The catheter supports pulsed-field ablation, radio-frequency energy, or a combination of both, giving physicians…
- Product Launch and TransitionImportance 31 · Surprise 42Abbott received U.S. FDA clearance for the TactiFlex Duo ablation catheter to treat atrial fibrillation. The catheter supports pulsed-field ablation, radio-frequency energy, or a combination of both, giving…
News · 2026-09-08
- Regulatory Approval MilestonesImportance 41 · Surprise 60Abbott received U.S. FDA approval for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, for treating patients with challenging atrial fibrillation (AFib) cases. The catheter combines pulsed field ablation (PFA)…
News · 2026-09-05
- Regulatory Approval MilestonesImportance 41 · Surprise 60Abbott received U.S. FDA approval for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, for treating patients with challenging atrial fibrillation (AFib) cases. The catheter combines pulsed field ablation (PFA)…
News · 2026-09-02
- Regulatory Approval MilestonesImportance 41 · Surprise 60Abbott received U.S. FDA approval for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, for treating patients with challenging atrial fibrillation (AFib) cases. The catheter combines pulsed field ablation (PFA)…
News · 2026-08-31
- Product Launch and TransitionImportance 31 · Surprise 42Abbott launched Similac 360 Total Care Made With Whole Milk, described as the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. The product uses whole milk in a fat blend intended to…
News · 2026-08-29
- CGM Market DemandImportance 34 · Surprise 42Abbott and Dexcom are anticipating expanded Medicare coverage for continuous glucose monitors (CGMs) to include people with Type 2 diabetes who do not use insulin. The expansion could broaden access to glucose sensors…
- Diabetes Technology ExpansionImportance 34 · Surprise 42The U.S. Medicare program is expected to expand continuous glucose monitor (CGM) coverage to people with Type 2 diabetes who do not use insulin. The policy change could make Abbott’s glucose sensors available to…
News · 2026-08-27
- Regulatory Approval MilestonesImportance 38 · Surprise 60Abbott received CE Mark approval for its next-generation Amulet 360 left atrial appendage occluder in Europe on August 27, 2026. The device is intended for patients with non-valvular atrial fibrillation who face stroke…
- Product Launch and TransitionImportance 38 · Surprise 60Abbott received CE Mark approval in Europe for its next-generation Amulet 360 Left Atrial Appendage Occluder. The device is designed for patients with non-valvular atrial fibrillation and seals the left atrial…
News · 2026-08-26
- Libre Duo Regulatory ApprovalImportance 38 · Surprise 60Abbott received FDA authorization on August 26, 2026, for the Libre Duo 10 Day system, the first biowearable designed to continuously sense both glucose and ketones. The device is intended to alert people with diabetes…
News · 2026-08-25
- Infant Formula LitigationImportance 52 · Surprise 42Abbott agreed to pay $670 million to settle NEC claims brought by approximately 2,000 individuals involving preterm infant formula. The settlement also resolves a prior $495 million verdict, while Abbott continues to…
- Libre Duo Regulatory ApprovalImportance 38 · Surprise 60Abbott received U.S. FDA De Novo authorization for Libre Duo 10 Day, the first continuous biowearable designed to monitor both glucose and ketone levels. The device is indicated for people aged 2 and older, provides up…
News · 2026-08-21
- Infant Formula LitigationImportance 53 · Surprise 60Abbott agreed to pay approximately $670 million to settle about 2,000 claims alleging that its specialty formulas for premature infants caused necrotizing enterocolitis (NEC). The settlement includes resolution of the…
- Guidance / OutlookImportance 51 · Surprise 60Abbott reportedly raised its annual 2026 profit forecast after stronger-than-expected second-quarter results. The revised outlook was attributed primarily to demand for cancer diagnostics and medical devices. The…
- Diabetes Technology EcosystemImportance 31 · Surprise 42MiniMed Group has begun commercial U.S. shipments of the MiniMed Flex insulin-pump system integrated with Abbott's Instinct sensor. The system combines a discreet, app-controlled pump with a longer-wear sensor to…
- CGM Competition and PricingImportance 20 · Surprise 24Abbott continues to face competitive and pricing pressure in continuous glucose monitoring. The pressure affects the company's CGM franchise even as demand remains strong across other medical-device categories. Abbott…
- Diagnostic Market DemandImportance 17 · Surprise 24Abbott is seeing strong demand for cancer diagnostics, supporting growth in its Diagnostics business. The reported demand is attributed to increasing oncology screening activity and is expected to accelerate in the…
8-K · 2026-08-20
- Infant Formula LitigationImportance 56 · Surprise 58Abbott agreed with three law firms to resolve the Gill case and claims involving approximately 2,000 additional individuals concerning specialty formulas for preterm infants. The aggregate settlement is approximately…
- Litigation and Legal RiskImportance 56 · Surprise 58Abbott agreed to resolve the Gill case and NEC claims involving approximately 2,000 additional individuals for an aggregate amount of approximately $670 million, avoiding payment of roughly $600 million for the Gill…
- Products and TechnologyImportance 10 · Surprise 6Abbott’s preterm infant formulas are specialty nutrition products designed for premature and low-birth-weight infants requiring more calories and nutrients than full-term infants. The products include Similac Special…
- End-Market Demand TrendsImportance 10 · Surprise 24Approximately one in every 10 infants born in the United States is premature, according to the CDC. Demand for preterm formula is supported by insufficient supplies of mothers’ own milk and donor human milk for some…
News · 2026-08-20
- Infant Formula LitigationImportance 46 · Surprise 42Abbott agreed to pay approximately $670 million to resolve the Gill case and claims from about 2,000 individuals involving specialty formulas for premature infants. The settlement follows a Missouri jury verdict of…
News · 2026-08-19
- Guidance / OutlookImportance 57 · Surprise 76Abbott raised its full-year 2026 earnings outlook after second-quarter results exceeded expectations. The revised outlook is supported by demand for cancer diagnostics and Medical Devices, as well as the Exact Sciences…
- Revenue Performance and MixImportance 31 · Surprise 32Abbott reported 4.8% year-over-year sales growth in the second quarter of 2026, with revenue reaching $12.59 billion. Growth was driven by Nutrition, Diagnostics—including cancer diagnostics—and Medical Devices, with…
- Gross Margin DriversImportance 31 · Surprise 32Abbott’s adjusted gross margin increased 100 basis points year over year to 58.0% in the second quarter of 2026. Margin expansion accompanied 4.8% sales growth and was attributed to stronger performance in Diagnostics…
- Product Launch and TransitionImportance 31 · Surprise 42MiniMed Group commercially shipped the MiniMed Flex insulin pump in the United States with Abbott Laboratories’ Instinct continuous glucose sensor. The app-controlled system pairs an insulin pump with Abbott’s smallest…
News · 2026-08-18
- Revenue Performance and MixImportance 54 · Surprise 40Abbott Laboratories reported second-quarter revenue of $12.59 billion, up 13% year over year. The quarterly result exceeded analyst revenue expectations, according to the third-party reports. The reports also cited…
- Quarterly Dividend DeclarationImportance 13 · Surprise 6Abbott declared a quarterly dividend of $0.63 per share. The dividend represents an annualized yield of approximately 2.3%, based on the reported share price. The reports linked the dividend announcement to Abbott’s…
News · 2026-08-17
- Revenue Performance and MixImportance 37 · Surprise 6Abbott reported quarterly revenue of $12.59 billion, exceeding analyst expectations. Quarterly earnings were $1.31 per share, also above expectations. Coverage cited strength in Abbott’s Established Pharmaceutical…
- Google Health PartnershipImportance 31 · Surprise 42Abbott’s Lingo glucose monitor is being integrated with the Google Health app through an Alphabet partnership. The connectivity expands the digital ecosystem around Lingo, enabling users to bring glucose-monitoring…
- Partner Ecosystem ExpansionImportance 31 · Surprise 42Abbott and the National Association of Community Health Centers launched a multi-year Food for Health initiative in the United States to integrate nutrition services into primary care. The program will provide…
- Food for Health InitiativeImportance 31 · Surprise 42Abbott and the National Association of Community Health Centers launched a multi-year Food for Health initiative in the United States. The program will provide Community Health Centers with certification, training,…
News · 2026-08-15
- Revenue Performance and MixImportance 33 · Surprise 6Abbott Laboratories generated €37.74 billion of revenue over the last year, according to the reported segment breakdown. Medical Devices was the company’s largest segment at €18.21 billion. The United States was the…
- Google Health PartnershipImportance 31 · Surprise 42Abbott has a new AI partnership with Alphabet involving its Lingo continuous glucose monitor. The collaboration expands Abbott’s digital-health and continuous-glucose-monitoring ecosystem beyond the sensor itself. The…
- Quarterly Dividend DeclarationImportance 10 · Surprise 6Abbott Laboratories declared a quarterly dividend of $0.63 per share. The dividend was reported alongside Abbott’s second-quarter investment and ownership disclosures. The announced per-share distribution provides a…
News · 2026-08-14
- Revenue Performance and MixImportance 37 · Surprise 6Abbott reported quarterly revenue of $12.59 billion, exceeding Wall Street expectations. The company also reported quarterly EPS of $1.31 alongside the revenue result. The reported earnings beat was attributed to…
- Diagnostics Collaboration ExpansionImportance 31 · Surprise 42Abbott will sell Freenome’s SimpleScreen CRC colorectal-cancer blood test in the United States. Freenome received FDA breakthrough-device designation for its SimpleScreen Lung test for high-risk individuals. The two…
- Partner Ecosystem ExpansionImportance 31 · Surprise 42Abbott will sell Freenome’s SimpleScreen CRC blood-based colorectal cancer test in the United States. Freenome’s SimpleScreen Lung test received FDA breakthrough device designation for detecting early lung cancer in…
- Regulatory Approval MilestonesImportance 31 · Surprise 42Freenome received FDA breakthrough device designation for its SimpleScreen Lung blood biopsy for early lung-cancer detection in high-risk individuals. The test uses DNA methylation patterns and artificial-intelligence…
- Quarterly Dividend DeclarationImportance 13 · Surprise 6Abbott declared a quarterly dividend of $0.63 per share. The reported dividend declaration accompanied quarterly revenue of $12.59 billion and EPS of $1.31. The $0.63-per-share rate represents a recurring quarterly…
News · 2026-08-13
- Revenue Performance and MixImportance 49 · Surprise 22Abbott Laboratories reported quarterly revenue of $12.59 billion, up 13% year over year. Quarterly EPS was $1.31, and the results exceeded analysts’ expectations. The digest did not provide segment-level revenue,…
- Product Launch and TransitionImportance 34 · Surprise 42Wolfe Research identified Abbott’s Volt pulsed-field ablation (PFA) catheter launch as a catalyst for the company’s 2027 medical-device outlook. The firm also cited an expected recovery in Abbott’s Libre continuous…
- Quarterly Dividend DeclarationImportance 9 · Surprise 6Abbott Laboratories declared a quarterly dividend of $0.63 per share. The dividend was cited in connection with the company’s recent earnings report and analyst coverage. The digest did not provide the record date,…
News · 2026-08-12
- Revenue Performance and MixImportance 43 · Surprise 22Abbott reported quarterly revenue of $12.59 billion, up 13% year over year. The revenue result exceeded analyst expectations for the quarter. Adjusted EPS was $1.31, also above consensus estimates.
- Google Health PartnershipImportance 31 · Surprise 42Abbott partnered with Google Health to integrate glucose insights from its Lingo biowearable into the Google Health app. The collaboration uses artificial intelligence to provide personalized metabolic-health coaching…
- Capital Return ProgramImportance 13 · Surprise 6Abbott declared a quarterly dividend of $0.63 per share. The declared rate represents an annualized dividend of approximately $2.52 per share. The dividend announcement accompanied quarterly revenue of $12.59 billion…
News · 2026-08-11
- Revenue Performance and MixImportance 37 · Surprise 6Abbott reported $12.59 billion in quarterly revenue and adjusted earnings of $1.31 per share, exceeding analyst expectations. Medical Devices is experiencing strong growth, with continuous glucose monitoring sales…
- Google Health Glucose PartnershipImportance 31 · Surprise 42Abbott entered a multi-year collaboration with Google Health to integrate glucose insights from its Lingo over-the-counter continuous glucose monitor into the Google Health app. The partnership will support AI-powered…
- Google Health PartnershipImportance 31 · Surprise 42Abbott entered a multi-year collaboration with Google Health on August 11, 2026, integrating ongoing glucose insights from Abbott’s over-the-counter Lingo biowearable continuous glucose monitor into Google’s health…
- Capital Return ProgramImportance 13 · Surprise 6Abbott announced a quarterly dividend of $0.63 per share. The dividend implies an annualized yield of 2.3%. The dividend announcement accompanied quarterly revenue of $12.59 billion and adjusted earnings of $1.31 per…